- 78% of patients with advanced melanoma who discontinued anti-programmed cell death protein 1 (PD-1) therapy in the absence of disease progression or treatment-limiting toxicity remained progression-free at median 18-month follow-up.
- Progression was less likely with achievement of complete response (CR).
Why this matters
- The optimal duration of anti-PD-1 therapy is not well established.
- Median time on treatment, 12 (range, 0.7-43) months.
- At discontinuation, 63% of patients had achieved CR, 24% had achieved partial response (PR), and 9% had stable disease.
- 78% remained progression-free at a median follow-up of 18 (range, 0.7-48) months posttreatment.
- Patients with CR had lower risk for progression (14%) than those with PR (32%; HR, 2.99; P=.002) or SD (50%; HR, 5.15; P<.001>
- Among patients with CR, those treated ≥6 months (median PFS, 18.9 months vs not reached; P<.05>
- No difference in progression with CR in patients treated for 6-12, 12-18, 18-24, or ≥24 months (P>.05 for all).
- 32% of patients with disease progression achieved a new CR or PR after retreatment with anti-PD-1 therapy.
- Real-world study of 185 patients with advanced melanoma who discontinued anti-PD-1 therapy (N=167 pembrolizumab, 18 nivolumab),
- Funding: None.
- Retrospective design.